46 results on '"Pérez-Alós, Laura"'
Search Results
2. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
3. High anti-SARS-CoV-2 seroprevalence among unvaccinated mother–child pairs from a rural setting in north-eastern Tanzania during the second wave of COVID-19
4. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
5. #887 Complement biomarkers in IgA nephropathy and IgA vasculitis with renal involvement: can urine rather than blood be the answer?
6. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
7. SARS-CoV-2 anti-RBD and anti-N protein responses are differentially regulated between mother-child pairs: insight from a national study cohort at the Faroe Islands.
8. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
9. Diverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands
10. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial
11. Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
12. MAP‐2:CD55 chimeric construct effectively modulates complement activation
13. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies.
14. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
15. 141 Characterization of the interaction of mannose-binding lectin with variant SARS-CoV-2 spike proteins
16. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial
17. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
18. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
19. SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments
20. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study
21. Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
22. Factors influencing the immune response over 15 months after SARS‐CoV‐2 infection: A longitudinal population‐wide study in the Faroe Islands
23. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19
24. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
25. Factors influencing the immune response over 15 months after SARS‐CoV‐2 infection: A longitudinal population‐wide study in the Faroe Islands.
26. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19.
27. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
28. Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients With Chronic Pulmonary Diseases
29. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
30. Humoral response to two doses of BNT162b2 vaccination in people with HIV
31. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
32. Antibody‐dependent neutralizing capacity of the SARS‐CoV‐2 vaccine BNT162b2 with and without previous COVID‐19 priming
33. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain
34. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands
35. SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
36. Humoral response to two doses of BNT162b2 vaccination in people with HIV.
37. Vaccine monitoring shows that focused immunization with SARS-CoV-2 receptor-binding domain provides a better neutralizing antibody response than full-length spike protein
38. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals
39. SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals
40. Comparison of induction methods for supersaturation: pH shift versus solvent shift
41. Combining MAP‐1:CD35 or MAP‐1:CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade
42. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
43. Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)
44. Humoral immunity after a booster dose of COVID-19 vaccine in patients with psoriasis treated with methotrexate and biologics: a cohort study.
45. CL-11 circulates in serum as functionally distinct isoforms.
46. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.